title: [Transconjunctival sutureless pars plana vitrectomy and Brilliant Peel (BP)-assisted ILM peeling in patients with macular holes].
abstract: OBJECTIVE
  The aim of this study was to evaluate the visual and anatomic outcome after 23-gauge transconjunctival sutureless pars plana vitrectomy and Brilliant Peel (BP)-assisted ILM peeling in patients with macular holes.
  
  
  METHODS
  In a consecutive retrospective study in 41 eyes of 41 patients with macular holes a standardised 23-G transconjunctival sutureless pars plana vitrectomy with ILM-peeling and gas tamponade was performed. All patients underwent preoperative measurements of visual acuity (VA), the maximum hole diameter, basis, height, and intraretinal changes using high resolution optical coherence tomography (SD-OCT; Spectralis; Heidelberg Engineering). Main outcome measures included visual acuity 1, 3, and 6 months after surgery and the closure rate. We also evaluated photoreceptor inner/outer segment (IS/OS) integrity as seen in SD-OCT for correlation with visual outcomes after macular hole surgery.
  
  
  RESULTS
  At baseline the mean best corrected visual acuity (BCVA) was 0.2 (0.77 logMAR). BCVA improved significantly to 0.4 (0.46 logMAR) after 1 month, to 0.44 (0.41 logMAR) after 3 months and to 0.58 (0.28 logMAR) after 6 months, respectively. A closure rate of 95.1 % was achieved. The morphological parameter photoreceptor IS/OS integrity was measured semiquantitatively and showed a positive correlation to BCVA.
  
  
  CONCLUSIONS
  Transconjunctival sutureless pars plana vitrectomy and Brilliant Peel (BP)-assisted ILM peeling in patients with macular holes is a very safe procedure and leads to good functional and anatomic results. The integrity of the IS/OS segment is a good predictive parameter for BCVA improvement after macular hole surgery.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar, Techninische Universtät München, Ismaningerstrasse 22, Munich. Mathias.Maier@mri.tum.de
authors.forename: M M
authors.initials: MM
authors.lastname: Maier
authors.forename: S
authors.initials: S
authors.lastname: Rass
authors.forename: C
authors.initials: C
authors.lastname: Mueller
authors.forename: N
authors.initials: N
authors.lastname: Feucht
authors.forename: C P
authors.initials: CP
authors.lastname: Lohmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000601:surgery*; D019773:Epiretinal Membrane / Q000473:pathology* / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012167:Retinal Perforations / Q000150:complications / Q000473:pathology* / Q000601:surgery*; D012189:Retrospective Studies; D012394:Rosaniline Dyes; D013537:Sutures; D016896:Treatment Outcome; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D014821:Vitrectomy / Q000379:methods*
chemical_list: D012394:Rosaniline Dyes; C004692:coomassie Brilliant Blue